Brazil and India Need Their Own Operation Warp Speed
(Bloomberg Opinion) -- Covid-19 is crushing developing countries such as India, Brazil and South Africa, and it won't help to simply tinker with the patents on life-saving vaccines made by a handful of pharmaceutical companies.
It's more crucial that the pharmaceutical industry's manufacturing and distribution expertise be brought to bear on this epic challenge, as Bloomberg Opinion's editorial board and my colleague Lionel Laurent have noted. Access to a recipe without access to an oven and serving trays won't put food in anyone's hands.
There's another element missing from this nascent rescue plan: sophisticated and effective public-private partnerships. Operation Warp Speed, one of the signature successes of the Trump administration, which otherwise bungled its pandemic response, worked because the federal government provided a financial backstop for companies to help them take on the myriad risks of vaccine development.
The White House seeded Warp Speed with $10 billion in federal funds. That money accelerated drug development — by allowing companies to conduct trials and manufacture vaccines on parallel tracks — and offered a guaranteed market. The feds became the buyer of last resort and stripped away production and sales uncertainties that typically slow or hobble drug development. Presto, risk removed.
A small group of pharmaceutical companies — including AstraZeneca Plc, GlaxoSmithKline Plc, Johnson & Johnson, Moderna Inc., Novavax Inc., Pfizer Inc. and Sanofi SA — received the lion's share of Warp Speed funding and support. As we now know, Moderna and Johnson & Johnson ultimately brought drugs to market that changed the pandemic's course. Pfizer, which also produced a miracle drug in record time, opted not to take federal money. But it was nevertheless assured that Warp Speed would buy its vaccine if approved. And Pfizer's partner, BioNTech SE, got $445 million from the German government to help the smaller company develop and manufacture its innovative messenger RNA technology.
All of this government aid highlights another flaw in the debate over Covid-19 vaccine intellectual property and whether the  Biden administration is right to support waiving patents temporarily. The World Trade Organization is reviewing a proposal to do that, and some pharmaceutical companies and Wall Street analysts have complained that any such measure would amount to pickpocketing.
Patents and IP laws have always existed, ideally, to protect the brainchildren of innovators and guarantee that they get their rightful share of the bounty from popular or groundbreaking products. In more recent decades, big companies have used patent claims to stifle competitors.
The pharmaceutical industry should be compensated for creativity and risk-taking, of course, and protected from theft. But drug companies, often buttressed with public funding, have also used patents to squelch rivals and maintain lucrative pricing regimes, even when that isn't in the public interest. Just think back to the criticism directed at Gilead Sciences Inc. last year for how it priced remdesivir, which it touted as a Covid-19 remedy.
The vaccines on the market now didn't spring into existence solely because of private capital. Taxpayers helped foot a substantial part of the bill, and their interests should be served as well. Moderna, which arguably would never have brought a drug to market without government aid, has already said it won't enforce its vaccine patent rights during the pandemic.
So the Biden administration has some reason to support the patent waiver under consideration at the WTO. But even if the waiver goes through, it won't remove the bigger obstacles in the way of getting vaccines to developing countries. That will take more public-private partnerships.
For an Operation Warp Speed to take root in countries such as India or Brazil, their political leaders will need as much public leverage as the U.S. and Europe were able to apply. Unfortunately, these countries' leaders, Narendra Modi in India and Jair Bolsonaro in Brazil, have both paraded doctrinaire free-market agendas at the expense of constructive public planning. Engineering a public-private response to Covid-19 may elude them.
Operation Warp Speed proved that public-private partnerships can create the force needed to mount a huge and effective vaccine program. Waiving patents won't matter without a broader local push to develop, manufacture and distribute vaccines at reasonable prices. Governments in developing countries need to play a pivotal role in that process, and too many of them don't appear to be up to the task.
This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.
Timothy L. O'Brien is a senior columnist for Bloomberg Opinion.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.